Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: Docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
Sang Gyu Lee, Young Geon Jee, Hyun Chul Chung, Sung Bae Kim, Jungsil Ro, Young Hyuck Im, Seock Ah Im, Jae Hong Seo
Dive into the research topics of 'Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: Docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)'. Together they form a unique fingerprint.